Aberrant Epigenetic Alteration of PAX1 Expression Contributes to Parathyroid Tumorigenesis | Zendy

Priyanka Singh | Zendy; Sanjay Kumar Bhadada | Zendy; Ashutosh Kumar Arya | Zendy; Uma Nahar Saikia | Zendy; Naresh Sachdeva | Zendy; Divya Dahiya | Zendy; Jyotdeep Kaur | Zendy; Maria Luisa Brandi | Zendy; Sudhaker D. Rao | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Aberrant Epigenetic Alteration of PAX1 Expression Contributes to Parathyroid Tumorigenesis

Author(s) -

Priyanka Singh,

Sanjay Kumar Bhadada,

Ashutosh Kumar Arya,

Uma Nahar Saikia,

Naresh Sachdeva,

Divya Dahiya,

Jyotdeep Kaur,

Maria Luisa Brandi,

Sudhaker D. Rao

Publication year - 2021

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/clinem/dgab626

Subject(s) - epigenetics , parathyroid hormone , cancer research , bisulfite sequencing , dna methylation , microbiology and biotechnology , ezh2 , histone , chromatin immunoprecipitation , biology , gene expression , promoter , medicine , gene , genetics , calcium

Context Primary hyperparathyroidism (PHPT) results from the hypersecretion of parathyroid hormone from parathyroid tumors. A transcription factor, namely Paired box1 (PAX1), is active in parathyroid gland development. Objective We aimed to study potential epigenetic-mediated mechanism of PAX1 gene in sporadic parathyroid adenomas. Methods In parathyroid adenomas tissues, we analyzed the DNA methylation via bisulfite-specific polymerase chain reaction (BSP) and histone modifications via chromatin immunoprecipitation in regulating the differential expression of PAX1. Results The results showed that mRNA and protein expression of PAX1 was significantly reduced in parathyroid adenomas. Bisulfite sequencing demonstrated hypermethylation in the promoter region of PAX1 (35%; 14/40) and lower levels of histone 3 lysine 9 acetylation (H3K9ac) were observed on the promoter region of PAX1 (6-fold; P < .004) in parathyroid adenomas. Furthermore, upon treatment with a pharmacologic inhibitor, namely 5′aza-2 deoxycytidine, in rat parathyroid continuous cells, we found re-expression of PAX1 gene. Conclusion Our study not only reveals expression of PAX1 is epigenetically deregulated but also paves a way for clinical and therapeutic implications in patients with PHPT.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research